Navigation thread
Hepatic oncology (BCLC)
Featured publications
-
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
Sanduzzi-Zamparelli, M; Sapena, V; Iserte, G; Granel, N; Llarch, N;(...)Díaz, A; Fuster-Anglada, C; Ayuso, C; Rimola, J; Torres, F.Reference:Journal Of Hepatology 2022.
-
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Sapena, V; Bruix, J; Reig, M; Enea, M; Celsa, C;(...)Zanetto, A; Shalaby, S; Russo, FP; Bielen, R; Trevisani, F.Reference:Gut 2022.
-
Regorafenib efficacy after sorafenib in patients with recurrent HCC after liver transplantation: a retrospective study
Iavarone, M; Invernizzi, F; Mazza, S; Donato, MF; Lampertico, P;(...)Soteras, GA; Villadsen, GE; Crespo, G; Prince, R; Scudeller, L.Reference:Liver Transplantation 2021.
-
Antiviral therapy in the palliative setting of HCC (BCLC B and C)
Reig, M; Cabibbo, G;Reference:Journal Of Hepatology 2021.
-
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
Corominas, J; Sapena, V; Sanduzzi-Zamparelli, M; Millán, C; Samper, E;(...)Forner, A; Bruix, J; Boix, L; Reig, M; Torres, F.Reference:Cancers 2021.
-
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
Iavarone, Massimo; Invernizzi, Federica; Czauderna, Carolin; Sanduzzi-Zamparelli, Marco; Bhoori, Sherrie;(...)Varela, Maria; Woerns, Marcus-Alexander; Bruix, Jordi; Lampertico, Pietro; Reig, Maria.Reference:American Journal Of Transplantation 2019.
-
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Marino, Zoe; Darne, Anna; Lens, Sabela; Sapena, Victor; Diaz, Alba;(...)Ayuso, Carmen; Rios, Jose; Forns, Xavier; Bruix, Jordi; Reig, Maria.Reference:Journal Of Hepatology 2019.
-
New trials and results in systemic treatment of HCC.
Reig M; da Fonseca LG; Faivre S ;Reference:Journal Of Hepatology 2018.
-
Complete response under sorafenib in patients with hepatocellular carcinoma. Relationship with dermatologic adverse events.
Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F;(...)Huertas C; Minguez B; Ayuso C; Bruix J; Reig M .Reference:Hepatology 2018.